Abstract：
:Advances in drug discovery have led to the use of effective targeted agents in the treatment of hematologic malignancies. Drugs such as proteasome inhibitors in multiple myeloma and tyrosine kinase inhibitors in chronic myeloid leukemia and non-Hodgkin lymphoma have changed the face of treatment of hematologic malignancies. There are several reports of cardiovascular adverse events related to these newer agents. Both "on-target" and "off-target" effects of these agents can cause organ-specific toxicity. The need for long-term administration for most of these agents requires continued monitoring of toxicity. Moreover, the patient population is older, often over 50 years of age, making them more susceptible to cardiovascular side effects. Additional factors such as prior exposure to anthracyclines often add to this toxicity. In light of their success and widespread use, it is important to recognize and manage the unique side effect profile of targeted agents used in hematologic malignancies. In this article, we review the current data for the incidence of cardiovascular side effects of targeted agents in hematologic malignancies and discuss a preemptive approach towards managing these toxicities.
journal_name
Curr Hematol Malig Repjournal_title
Current hematologic malignancy reportsauthors
Sethi TK,Basdag B,Bhatia N,Moslehi J,Reddy NMdoi
10.1007/s11899-017-0369-ysubject
Has Abstractpub_date
2017-06-01 00:00:00pages
257-267issue
3eissn
1558-8211issn
1558-822Xpii
10.1007/s11899-017-0369-yjournal_volume
12pub_type
杂志文章,评审abstract：:Chronic myelomonocytic leukemia is a clonal malignancy of the ageing hematopoietic stem cell characterized by a biased differentiation leading to persistent monocytosis and inconstant hypersensitivity of myeloid progenitors to granulo-monocyte colony-stimulating factor (GM-CSF). Cytogenetic abnormalities identified in...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-014-0225-2
更新日期：2014-12-01 00:00:00
abstract：PURPOSE OF REVIEW:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy derived from plasmacyoid dendritic cells whose biology, clinical features, and treatment options are increasingly better understood. RECENT FINDINGS:TCF4 is a master regulator that drives donwstream transcriptional programs in ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0489-z
更新日期：2018-12-01 00:00:00
abstract：:C. difficile infection (CDI), the most common cause of hospital-acquired diarrhea, is very frequent after hematopoietic stem cell transplantation (HSCT). Recent publications suggest it affects between 6 % and 20 % of HSCT recipients during the first year and is more common following allogeneic transplant (allo-HSCT). ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-013-0193-y
更新日期：2014-03-01 00:00:00
abstract：:Myelodysplastic syndromes (MDS), or myelodysplasia, are a heterogeneous group of bone marrow disorders characterized by progressive cytopenias and a propensity to evolve into acute leukemia. The only curative strategy in the treatment of MDS is stem cell transplantation. The advent of hypomethylating agents and, more ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章
doi：10.1007/s11899-008-0002-1
更新日期：2008-01-01 00:00:00
abstract：:No therapy is uniformly effective in the management of immunoglobulin light chain amyloidosis (AL amyloidosis). Despite the common generalization, therapy is highly effective. Options available to patients with AL amyloidosis include high-dose therapy, but this is applicable to only about one fourth of patients. Thera...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-009-0013-6
更新日期：2009-04-01 00:00:00
abstract：:Hodgkin's lymphoma (HL) is a relatively rare disease accounting for 15 % of all lymphoma. This disease has developed from an incurable disease to the adult malignancy with the most favorable prognosis. With current therapeutic approaches consisting of polychemo- and small-field radiotherapy, up to 80 % of all patients...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-015-0262-5
更新日期：2015-09-01 00:00:00
abstract：:In patients with acute leukemia, measurements of minimal residual disease (MRD) provide unique information on response to treatment. The most useful currently available MRD assays are polymerase chain reaction amplification of fusion transcripts and rearranged antigen-receptor genes and flow cytometric detection of ab...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章
doi：10.1007/s11899-008-0022-x
更新日期：2008-07-01 00:00:00
abstract：PURPOSE OF REVIEW:In this review article, we will highlight ethical issues faced by hematologists due to a growing constellation of expensive diagnostics and therapeutics in hematology. We outline the important issues surrounding this topic including stakeholders, cost considerations, and various ethical challenges sur...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-020-00599-w
更新日期：2020-10-01 00:00:00
abstract：:The original version of this article unfortunately contained a mistake. The conflict of interest statement was incorrect. The corrected statement is given below. ...
journal_title：Current hematologic malignancy reports
pub_type： 已发布勘误
doi：10.1007/s11899-018-0488-0
更新日期：2019-02-01 00:00:00
abstract：:The DNA hypomethylating agents (HMAs) azacitidine and decitabine are currently the most frequently administered disease-modifying therapies for patients with higher-risk myelodysplastic syndromes (MDS). However, azacitidine and decitabine are not curative, the median response duration is 11-15 months, and only 10-20 %...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-015-0273-2
更新日期：2015-09-01 00:00:00
abstract：PURPOSE OF REVIEW:Older adults with hematologic malignancy are a growing demographic. Estimating risk of chemotherapy toxicity based on age alone is an unreliable estimate of quality of life, functional capacity, or risk of treatment complications. RECENT FINDINGS:Dedicated geriatric assessment tools can aid the clini...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0454-x
更新日期：2018-06-01 00:00:00
abstract：PURPOSE OF REVIEW:The use of circulating tumor DNA (ctDNA) for the purposes of diagnosis, prognosis, assessment of treatment response, and monitoring for relapse is a new and developing field in lymphoma. This review aims to summarize many of the most recent advances in ctDNA applications. RECENT FINDINGS:Recent studi...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0468-4
更新日期：2018-10-01 00:00:00
abstract：:Myeloproliferative neoplasms (MPNs) are stem cell-derived clonal myeloid malignancies characterized by a unique somatic mutational profile since three mutually exclusive mutations (JAK2V617F, MPL, and CALR) sustain the great majority of the cases. However, clinical observation that autoimmune diseases may predispose t...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-014-0227-0
更新日期：2014-12-01 00:00:00
abstract：:Allogeneic haematopoietic cell transplantation continues to be an important curative therapy for acute lymphoblastic leukaemia (ALL). Traditionally accepted indications for allografting adult ALL patients need reevaluation in light of outcomes with paediatric-like intensive regimens. Minimal residual disease status an...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-017-0371-4
更新日期：2017-04-01 00:00:00
abstract：PURPOSE OF REVIEW:Social media has dramatically changed the access and exchange of information in healthcare and beyond. A variety of platforms and resources exist allowing blood and marrow transplant providers, researchers, and patients to interact. We review the adoption of social media by the transplantation communi...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0487-1
更新日期：2018-12-01 00:00:00
abstract：PURPOSE OF REVIEW:The Choosing Wisely® initiative, led by the American Board of Internal Medicine Foundation in collaboration with national professional medical societies, aims to help patients choose care that is essential, free from harm, and evidence-based. The American Society of Hematology has advocated practices ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-020-00593-2
更新日期：2020-08-01 00:00:00
abstract：PURPOSE OF REVIEW:Antibody-drug conjugates are a new class of therapeutic agents in the treatment of B cell malignancies. In this review, we summarize the recent developments of polatuzumab vedotin in the treatment of relapsed or refractory diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL). RECENT FIN...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-020-00572-7
更新日期：2020-04-01 00:00:00
abstract：:Advances in chemotherapy administration have made acute lymphoblastic leukemia (ALL) a curable disease; however, most patients will relapse, despite readily attaining a complete remission. Treatment of relapse has shown dismal results with little advances made in the recent decades. Antigenic-directed therapy of ALL c...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-012-0120-7
更新日期：2012-06-01 00:00:00
abstract：:The introduction of imatinib represented a breakthrough in the treatment of chronic myelogenous leukemia (CML). However, about 20% of patients treated in early chronic-phase CML are off therapy after 6 years because of resistance or intolerance, and most patients taking imatinib remain BCR-ABL-positive at the molecula...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章
doi：10.1007/s11899-008-0012-z
更新日期：2008-04-01 00:00:00
abstract：:Mycosis fungoides (MF) and its leukemic variant, Sézary syndrome (SS), are malignancies of skin-homing T cells that comprise the majority of cutaneous T cell lymphomas (CTCL). Treatment of CTCL is limited and can be approached by skin-directed therapy or systemic therapy. Recent investigations into the pathogenesis of...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-015-0293-y
更新日期：2015-12-01 00:00:00
abstract：:Follicular lymphoma (FL), the most common indolent lymphoma, typically presents in advanced-stage disease. Currently available therapy does not generally result in a curative outcome, but survival in FL has improved since the introduction of anti-CD20 monoclonal antibody immunotherapy. The goals of treatment include p...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-011-0099-5
更新日期：2011-12-01 00:00:00
abstract：:Morphologic dysplasia is an important factor in diagnosis of myelodysplastic syndrome (MDS). However, the role of dysplasia is changing as new molecular genetic and genomic technologies take a more prominent place in diagnosis. This review discusses the role of morphology in the diagnosis of MDS and its interactions w...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-017-0405-y
更新日期：2017-10-01 00:00:00
abstract：:The prognosis value of interim positron emission tomography (PET) remains controversial in diffuse large B-cell lymphoma (DLBCL) patients because of the absence of consensus on criteria able to early identify good and bad responders to treatment. Visual interpretation using the International Harmonization Project (IHP...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-012-0129-y
更新日期：2012-09-01 00:00:00
abstract：PURPOSE OF REVIEW:Hematopoietic cell transplant (HCT) patients are required to have a caregiver present for up to 100 days post-transplant. Caregivers provide essential support during HCT but experience immense stress and burden. Increasing research has developed interventions for HCT caregivers. This review systematic...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0445-y
更新日期：2018-06-01 00:00:00
abstract：PURPOSE OF REVIEW:Artificial intelligence (AI), and in particular its subcategory machine learning, is finding an increasing number of applications in medicine, driven in large part by an abundance of data and powerful, accessible tools that have made AI accessible to a larger circle of investigators. RECENT FINDINGS:...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-020-00575-4
更新日期：2020-06-01 00:00:00
abstract：:Acute promyelocytic leukemia (APL) is characterized by coagulopathy, leukopenic presentation and sensitivity to anthracyclines, all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). For the last 25 years, APL has been treated with a combination of ATRA and chemotherapy for induction followed by consolidation and ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-014-0205-6
更新日期：2014-06-01 00:00:00
abstract：:Progress in the understanding of the biology of chronic lymphocytic leukemia and in the development of new and effective therapies has generated a shift in treatment paradigms within only a few years. Traditional chemotherapy agents such as alkylators or nucleoside analogs are rapidly being replaced by combination reg...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-006-0006-7
更新日期：2006-12-01 00:00:00
abstract：:Multiple myeloma is a disorder of terminally differentiated plasma cells, characterized by immune dysfunction, deregulated signaling within the bone marrow stromal compartment, and a microenvironment that fosters immunosuppression. Immunomodulatory techniques, such as allogeneic hematopoietic stem cell transplant (all...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-015-0283-0
更新日期：2015-12-01 00:00:00
abstract：:Just as a pawnshop owner who is unable to distinguish a genuine Rolex™ watch from a cheap knockoff courts financial ruin, the physician who fails to discriminate between authentic myelodysplastic syndromes (MDS) and conditions resembling MDS risks misinforming or harming patients. This review summarizes minimal criter...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-012-0140-3
更新日期：2012-12-01 00:00:00
abstract：:A high risk of arterial and venous thrombosis is the hallmark of chronic myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV) and essential thrombocythemia (ET). Clinical aspects, pathogenesis and management of thrombosis in MPN resemble those of other paradigmatic vascular diseases. The occurrence...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-013-0176-z
更新日期：2013-12-01 00:00:00
